How Stents Work to Open Blocked Arteries

A coronary stent is a small, expandable mesh tube — typically made from stainless steel or cobalt-chromium alloy — that is permanently implanted inside a coronary artery to hold it open after a blockage has been treated with balloon angioplasty. Since the first coronary stent was approved in the United States in 1994, stents have become the standard treatment for coronary artery blockages, dramatically reducing the need for bypass surgery and transforming the treatment of both stable coronary artery disease and acute heart attacks.

The Problem Before Stents: Balloon Angioplasty Alone

The era of coronary intervention began in 1977 when Swiss cardiologist Andreas Grüntzig performed the first percutaneous transluminal coronary angioplasty (PTCA) — inflating a tiny balloon inside a blocked coronary artery to compress the plaque and restore blood flow. Balloon angioplasty alone was remarkably effective — but had two major limitations:

Acute recoil: After the balloon was deflated, the artery often partially collapsed (recoiled) back to a narrowed state. Stents solved this by providing a rigid scaffold.

Restenosis: In approximately 30–40% of cases, the artery re-narrowed within 6 months due to cellular proliferation (smooth muscle cells growing into the treated area in response to the balloon injury). Drug-eluting stents substantially solved this problem.

How Stenting Is Performed

Coronary stenting is performed during cardiac catheterization (see Article 159):

1. Access and angiography: The blocked coronary artery is identified by contrast injection (angiography).

1. Guidewire crossing: A very thin (0.014-inch diameter) guidewire is advanced through the stenosis — a critical step requiring the physician to navigate the wire through or past the blockage.

1. Pre-dilation (if needed): A small balloon catheter is advanced over the guidewire to the site of the blockage and inflated to pre-open the lesion, making it easier to deliver the stent.

1. Stent delivery: The stent — mounted on a balloon catheter in its unexpanded (crimped) state — is advanced over the guidewire to the target site, positioned precisely across the blockage using fluoroscopic guidance.

1. Stent deployment: The balloon inside the stent is inflated, expanding the stent to its full diameter (typically 2.5–4 mm for coronary stents). The stent is pressed into the arterial wall and becomes permanently embedded in the vessel.

1. Balloon deflation and catheter removal: The balloon deflates and is withdrawn, leaving the stent permanently in place. The stent struts embed into the arterial wall and are eventually covered by endothelial cells (endothelialization) over 6–12 months.

1. Final angiography: Contrast injection confirms adequate blood flow through the stented segment.

The patient feels no pain during stent deployment — arteries have no pain fibers inside — though they may feel a warm flush from contrast injection.

Types Of Stents

Bare Metal Stents (Bms)

The original coronary stents — metallic mesh tubes with no medication coating. Dramatically reduced acute recoil compared to balloon angioplasty alone. However, restenosis remained a problem — in approximately 20–30% of cases, smooth muscle cell proliferation caused re-narrowing within 6–9 months. Largely replaced by drug-eluting stents for most applications but still used in specific situations.

Drug-Eluting Stents (Des)

Drug-eluting stents are coated with a polymer that slowly releases an antiproliferative drug (most commonly everolimus, sirolimus, or zotarolimus) into the local vessel wall over weeks to months. This drug inhibits smooth muscle cell proliferation, dramatically reducing restenosis rates to 5–10%.

Modern drug-eluting stents (second- and third-generation, developed since the mid-2000s) have thin struts and biocompatible polymer coatings that improve endothelialization and reduce thrombosis risk. They are the standard of care for the vast majority of coronary stenting procedures.

Bioresorbable Vascular Scaffolds (Bvs)

An experimental concept: stents made from biodegradable materials that provide temporary scaffolding and then dissolve over 2–3 years, leaving no permanent metallic implant. This approach is appealing conceptually but first-generation bioresorbable scaffolds had higher event rates than metal stents; further development is ongoing.

Stent Thrombosis: The Major Concern

Stent thrombosis — acute clot formation within the stent — is the most serious stent-related complication. If a clot forms within the stent, it can completely block the artery, causing a severe heart attack or death. Rates are approximately 0.5–1% per year; highest risk is in the first year after stenting.

Prevention: Dual antiplatelet therapy (DAPT) — aspirin plus a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) — is the cornerstone of stent thrombosis prevention. The stent surface is thrombogenic until it is covered by endothelial cells (endothelialized). DAPT prevents platelet-mediated clot formation during this vulnerable period.

Duration of DAPT: Typically 6–12 months for drug-eluting stents in stable CAD; potentially longer for high-risk situations (complex anatomy, ACS). Stopping antiplatelet therapy prematurely — especially in the first weeks — dramatically increases thrombosis risk. This is why patients must inform all physicians (including dentists and surgeons) about their coronary stent before any procedure.

Restenosis: Re-Narrowing After Stenting

Even with drug-eluting stents, approximately 5–10% of treated lesions develop restenosis — in-stent smooth muscle cell growth causing re-narrowing. Restenosis typically manifests as return of angina symptoms weeks to months after stenting (rarely causes abrupt total occlusion like de novo atherosclerosis). Treatment is typically repeat balloon angioplasty and drug-eluting balloon or re-stenting with another DES.

Living With A Coronary Stent

MRI safety: Modern stainless steel and cobalt-chromium stents are MRI-safe — patients can undergo MRI scanning after stent implantation (typically 6 weeks after, to allow endothelialization). Patients should inform MRI technicians about their stent.

Airport security: Stents do not trigger airport metal detectors.

Long-term outcomes: With appropriate DAPT, risk factor modification, and statin therapy, modern DES outcomes are excellent — most patients experience complete symptom relief and excellent long-term vessel patency.